Claims for Patent: 10,246,505

Summary for Patent: 10,246,505

Title:	Chimeric antigen receptors to control HIV infection
Abstract:	The present disclosure is directed to novel multispecific chimeric antigen receptor (CAR) proteins and DNA sequences encoding these proteins. The CARs comprise at least two extracellular domains fused, via a transmembrane domain to a cytoplasmic signaling domain comprising two signaling domains. The disclosure further relates to nucleic acids encoding the novel CARs, to host cells expressing the novel CARs, and to methods of using the CARs to co-stimulate effector functions in the cells and for using cells expressing the receptors for treatment of disease and viral infections. The disclosure also relates to methods of generating a recombinant T cell with reduced susceptibility to HIV infection.
Inventor(s):	Edward A. Berger, Mustafa H. Ghanem, Barna Dey
Assignee:	US Department of Health and Human Services
Application Number:	US15/039,384

Details for Patent 10,246,505

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Pfizer Inc.	ABRYSVO	respiratory syncytial virus vaccine	Injection	125769	May 31, 2023	10,246,505	2034-11-25

International Patent Family for US Patent 10,246,505

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2015077789
United States of America	2017267739
European Patent Office	3074419
Canada	2930587